Used in the treatment of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), particularly in patients who are resistant or intolerant to prior therapies including imatinib. It functions as a tyrosine kinase inhibitor, targeting BCR-ABL, SRC family kinases, and other related proteins involved in cancer cell proliferation and survival. Administered orally, it helps reduce tumor burden and control disease progression in specific leukemias. Also investigated for potential use in other cancers due to its broad kinase inhibition profile.